A Study of Experimental Medication BMS-986036 Given to Healthy Participants
| Status: | Completed |
|---|---|
| Conditions: | Gastrointestinal, Gastrointestinal, Gastrointestinal, Hepatitis |
| Therapuetic Areas: | Gastroenterology, Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | 21 - 55 |
| Updated: | 6/30/2018 |
| Start Date: | February 14, 2018 |
| End Date: | May 2, 2018 |
An Open-Label, Single-Dose, Fixed-Sequence Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986036 Administered to the Abdomen and Upper Arm in Healthy Participants
This is a study of experimental medication BMS-986036 given to healthy participants.
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
visit www.BMSStudyConnect.com
Inclusion Criteria:
- Healthy participant, as determined by no clinically significant deviations from normal
in medical history, physical examination, ECGs, and clinical laboratory determinations
- BMI of 18 to ≤ 40 kg/m2
Exclusion Criteria:
- Presence of any factors that would predispose the participant to infection (eg,
extensive periodontal disease that warrants surgical or medical treatment, unhealed
open wounds)
- Any bone trauma (fracture) or bone surgery (i.e. hardware placement, joint
replacement, bone grafting, or amputation) within 3 months of study drug
administration
- Known or suspected autoimmune disorder, excluding vitiligo
- Any history of known or suspected congenital or acquired immunodeficiency state or
condition that would compromise the participant's immune status
- Any significant acute or chronic medical illness
- Current or recent (within 3 months of study drug administration) gastrointestinal
disease
- Any major surgery within 6 weeks of study drug administration
- History of diabetes mellitus
Other protocol defined inclusion/exclusion criteria could apply
We found this trial at
1
site
Click here to add this to my saved trials
